Hemab Therapeutics Holdings initiates coverage with an overweight rating and $70 price target
COAG•J.P. Morgan initiated coverage of Hemab Therapeutics Holdings with an overweight rating and a $70 price target.
Related News
UBS reportedly weighs moving headquarters from Switzerland if capital rules tighten
UBS•
American Tower Corporation: Jefferies raises target price to $208 from $201
AMT•
TD Cowen raises ServiceNow target price to $165 from $140
NOW•
Tetra Tech: RBC cuts target price to $44 from $46
TTEK•
Axalta Coating Systems Ltd.: JP Morgan resumes coverage with neutral rating; target price $33
AXTA•